Skip to main content

Solid Tumor Clinical Trials

 

St. Jude Clinical Trials

3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors (3CAR)

Diseases Treated:

Solid Tumors

Eligibility:

Inclusion criteria include:

  • 21 years old or younger
  • Relapsed or refractory B7-H3-positive solid tumor

*First 3 patients must be at least 12 years old.

View Trial

ANGIO-A: Study of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Children and Young Adults with Solid Tumors

Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Diseases Treated:

Solid tumors
Hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma
Sarcomas
Malignant rhabdoid tumors
Desmoplastic small round cell tumors

Eligibility:

Part 1

  • 1–30 years old
  • Diagnosis of a solid tumor that has grown or has come back after treatment
  • Tumor accessible through biopsy

Part 2

  • 1–30 years old
  • Diagnosis of:
    • Hepatocellular carcinoma that has grown or has come back after treatment
    • Fibrolamellar hepatocellular carcinoma
    • Desmoplastic small round cell tumor
    • Malignant rhabdoid tumor that is not in the central nervous system
  • Tumor accessible through biopsy
View Trial

FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

Diseases Treated:

Neuroblastoma, pheochromocytoma

Eligibility:

This study is open to St. Jude patients only.

  • Known or suspected neuroblastoma or pheochromocytoma
  • At least 1 year old

 

View Trial

RBAPP: Smartphone App for Retinoblastoma

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

Diseases Treated:

Retinoblastoma

Eligibility:

This study is currently open only to patients at St. Jude Children's Research Hospital.

  • 7 years old or younger
  • Part I
    • Diagnosed with retinoblastoma and has not received any treatment OR
    • Diagnosed with cataracts and has not received any treatment OR
    • Diagnosed with glaucoma and has not received any treatment
  • Part II
    • Referred to an eye doctor to check for leukocoria or other eye conditions
  • Part III
    • Diagnosed with retinoblastoma and is receiving treatment
View Trial

Collaborative Clinical Trials

ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors

Diseases Treated:

Solid Tumors

Eligibility:

  • Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
  • Fully recovered from the acute toxic effects of all prior anticancer therapy
  • At least 1 but not more than 21 years of age
  • Able to swallow tablets whole
View Trial

LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors

Diseases Treated:

Solid tumors, Brain tumors

Eligibility:

  • 6 months to 21 years old
  • Solid tumor or brain tumor that has progressed or spread
  • Failed standard treatment
  • RET gene alteration
View Trial

MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

Diseases Treated:

Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

Eligibility:

  • Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
  • Between 12 years and 18 years old with diagnosis of melanoma OR
  • Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma
  • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
  • Appropriate liver and kidney functions
View Trial

NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma

Diseases Treated:

Neuroblastoma, ganglioneuroblastoma

Eligibility:

  • Participant has been enrolled on ANBLB1 (ANBL00B1).
  • Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
  • Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.

 

View Trial

PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors

Diseases Treated:

Recurrent, progressive, or refractory high-grade gliomas

Eligibility:

  • Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
  • Participant is 1 to 18 years of age
  • Participant has bi-measurable disease on MRI 
  • Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks

 

View Trial

PNOC013: Study of REGN2810 Immunotherapy in Children with Relapsed or Refractory Solid or CNS Tumors and Study of REGN2810 combined with radiation in Children with Newly Diagnosed or Recurrent Glioma

Diseases Treated:

Diffuse Intrinsic Pontine GliomaGlioma, CNS Tumor, Solid Tumor

Eligibility:

  • Diagnosed with one of the following:
  • Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)
View Trial
Close